{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:22:59Z","timestamp":1792686179789,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021R1I1A3058050"],"award-info":[{"award-number":["2021R1I1A3058050"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021R1A2C1012361"],"award-info":[{"award-number":["2021R1A2C1012361"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Parkinson\u2019s disease is a neurodegenerative disorder characterized by cardinal motor symptoms resulting from the loss of dopaminergic neurons in the substantia nigra pars compacta. Although current medications may alleviate its symptoms, Parkinson\u2019s disease remains incurable. Astaxanthin is an antioxidant and anti-inflammatory agent; however, its high susceptibility to oxidative degradation and low aqueous solubility limit its therapeutic efficacy. This study aimed to improve the pharmaceutical properties and neuroprotective effects of astaxanthin for Parkinson\u2019s disease treatment by using lactoferrin-conjugated astaxanthin-loaded liposomes (Lf-ASX-LPs). We successfully formulated Lf-ASX-LPs with high encapsulation efficiency (97.6%) and favorable physical characteristics (diameter: 109.8\u2009\u00b1\u20091.1\u00a0nm; polydispersity index: 0.18\u2009\u00b1\u20090.01; zeta potential: \u2212\u20099.5\u2009\u00b1\u20091.1 mV). Lf-functionalized liposomes demonstrated enhanced cellular uptake and permeation in a Transwell<jats:sup>\u00ae<\/jats:sup> study, showing a 16.7-fold higher internalization in SH-SY5Y cells over 24\u00a0h than those without Lf conjugation. Additionally, Lf functionalization enhanced brain penetration ability, as demonstrated by a biodistribution study using nude mice, compared to LPs without Lf conjugation. In vitro, Lf-ASX-LPs reduced cell loss by 20.1% and oxygen species by 30.0%, ameliorated the reduction in mitochondrial membrane potential under 1-methyl-4-phenylpyridinium-induced toxicity by 40.1%, and reduced extracellular nitric oxide levels under lipopolysaccharide-induced toxicity by 32.0%, indicating cytoprotective and antioxidant effects. In a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson\u2019s disease mouse model, treatment with Lf-ASX-LPs resulted in 5.0-, 3.1-, and 5.6-fold increases in dopamine levels, TH<jats:sup>+<\/jats:sup> fiber density, and TH<jats:sup>+<\/jats:sup> neurons, respectively, restoring dopaminergic neuron damage. The developed formulation also alleviated behavioral impairment and neuroinflammation, reducing astrocyte and microglial activation in the striatum and substantia nigra of the MPTP-treated animals. Thus, our formulation of Lf-ASX-LPs represents a promising strategy for providing neuroprotection and retarding Parkinson\u2019s disease progression.<\/jats:p>\n          <jats:p>\n            <jats:bold>Graphical abstract<\/jats:bold>\n          <\/jats:p>","DOI":"10.1186\/s12951-025-03104-8","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T06:15:14Z","timestamp":1738649714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Astaxanthin-loaded brain-permeable liposomes for Parkinson\u2019s disease treatment via antioxidant and anti-inflammatory responses"],"prefix":"10.1186","volume":"23","author":[{"given":"Thai-Duong","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shristi","family":"Khanal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunhee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsol","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Bohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikesh","family":"Rimal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyeun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"3104_CR1","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/j.pec.2021.01.028","volume":"104","author":"S Bayen","year":"2021","unstructured":"Bayen S, Carpentier C, Baran J, Cottencin O, Defebvre L, Moreau C, Devos D, Messaadi N. Parkinson\u2019s disease: content analysis of patient online discussion forums. A prospective observational study using Netnography. Patient Educ Couns. 2021;104:2060\u20136.","journal-title":"Patient Educ Couns"},{"key":"3104_CR2","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/nrn983","volume":"3","author":"J Lotharius","year":"2002","unstructured":"Lotharius J, Brundin P. Pathogenesis of parkinson\u2019s disease: dopamine, vesicles and \u03b1-synuclein. Nat Rev Neurosci. 2002;3:932\u201342.","journal-title":"Nat Rev Neurosci"},{"key":"3104_CR3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","volume":"403","author":"HR Morris","year":"2024","unstructured":"Morris HR, Spillantini MG, Sue CM, Williams-Gray CH. The pathogenesis of Parkinson\u2019s disease. Lancet. 2024;403:293\u2013304.","journal-title":"Lancet"},{"key":"3104_CR4","first-page":"9832839","volume":"2016","author":"F Magrinelli","year":"2016","unstructured":"Magrinelli F, Picelli A, Tocco P, Federico A, Roncari L, Smania N, Zanette G, Tamburin S. Pathophysiology of Motor Dysfunction in Parkinson\u2019s Disease as the Rationale for Drug Treatment and Rehabilitation. Parkinson\u2019s Disease. 2016;2016:9832839.","journal-title":"Parkinson\u2019s Disease"},{"key":"3104_CR5","doi-asserted-by":"publisher","first-page":"28910","DOI":"10.1021\/acsomega.3c04277","volume":"8","author":"X Li","year":"2023","unstructured":"Li X, Wang S, Duan S, Long L, Zhuo L, Peng Y, Xiong Y, Li S, Peng X, Yan Y, et al. Exploring the Therapeutic effects of multifunctional N-Salicylic acid tryptamine derivative against Parkinson\u2019s Disease. ACS Omega. 2023;8:28910\u201323.","journal-title":"ACS Omega"},{"key":"3104_CR6","doi-asserted-by":"crossref","unstructured":"MacMahon Copas AN, McComish SF, Fletcher JM, Caldwell MA. The Pathogenesis of Parkinson\u2019s Disease: A Complex Interplay Between Astrocytes, Microglia, and T Lymphocytes? Front Neurol. 2021;12.","DOI":"10.3389\/fneur.2021.666737"},{"key":"3104_CR7","doi-asserted-by":"crossref","unstructured":"Bj\u00f8rklund G, Gasmi A, Lenchyk L, Shanaida M, Zafar S, Mujawdiya PK, Lysiuk R, Antonyak H, Noor S, Akram M et al. The role of Astaxanthin as a Nutraceutical in Health and Age-related conditions. Molecules. 2022;27.","DOI":"10.3390\/molecules27217167"},{"key":"3104_CR8","doi-asserted-by":"publisher","first-page":"112179","DOI":"10.1016\/j.biopha.2021.112179","volume":"145","author":"Z Kohandel","year":"2022","unstructured":"Kohandel Z, Farkhondeh T, Aschner M, Pourbagher-Shahri AM, Samarghandian S. Anti-inflammatory action of astaxanthin and its use in the treatment of various diseases. Biomed Pharmacother. 2022;145:112179.","journal-title":"Biomed Pharmacother"},{"key":"3104_CR9","doi-asserted-by":"crossref","unstructured":"Medoro A, Davinelli S, Milella L, Willcox BJ, Allsopp RC, Scapagnini G, Willcox DC. Dietary astaxanthin: a promising antioxidant and anti-inflammatory Agent for Brain Aging and Adult Neurogenesis. Mar Drugs. 2023;21.","DOI":"10.3390\/md21120643"},{"key":"3104_CR10","doi-asserted-by":"publisher","first-page":"110762","DOI":"10.1016\/j.brainresbull.2023.110762","volume":"202","author":"L Wang","year":"2023","unstructured":"Wang L, Lu K, Lou X, Zhang S, Song W, Li R, Geng L, Cheng B. Astaxanthin ameliorates dopaminergic neuron damage in paraquat-induced SH-SY5Y cells and mouse models of Parkinson\u2019s disease. Brain Res Bull. 2023;202:110762.","journal-title":"Brain Res Bull"},{"key":"3104_CR11","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.yrtph.2015.10.013","volume":"73","author":"K Vega","year":"2015","unstructured":"Vega K, Edwards J, Beilstein P. Subchronic (13-week) toxicity and prenatal developmental toxicity studies of dietary astaxanthin in rats. Regul Toxicol Pharmacol. 2015;73:819\u201328.","journal-title":"Regul Toxicol Pharmacol"},{"key":"3104_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1089\/109662003765184741","volume":"6","author":"GA Spiller","year":"2003","unstructured":"Spiller GA, Dewell A. Safety of an astaxanthin-rich Haematococcus pluvialis algal extract: a randomized clinical trial. J Med Food. 2003;6:51\u20136.","journal-title":"J Med Food"},{"key":"3104_CR13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.foodhyd.2019.04.058","volume":"96","author":"R Edelman","year":"2019","unstructured":"Edelman R, Engelberg S, Fahoum L, Meyron-Holtz EG, Livney YD. Potato protein- based carriers for enhancing bioavailability of astaxanthin. Food Hydrocolloids. 2019;96:72\u201380.","journal-title":"Food Hydrocolloids"},{"key":"3104_CR14","doi-asserted-by":"publisher","first-page":"128497","DOI":"10.1016\/j.foodchem.2020.128497","volume":"343","author":"L Yang","year":"2021","unstructured":"Yang L, Qiao X, Gu J, Li X, Cao Y, Xu J, Xue C. Influence of molecular structure of astaxanthin esters on their stability and bioavailability. Food Chem. 2021;343:128497.","journal-title":"Food Chem"},{"key":"3104_CR15","doi-asserted-by":"crossref","unstructured":"Lombardo D, Kiselev MA. Methods of liposomes Preparation: formation and Control Factors of Versatile Nanocarriers for Biomedical and Nanomedicine Application. Pharmaceutics. 2022;14.","DOI":"10.3390\/pharmaceutics14030543"},{"key":"3104_CR16","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.jconrel.2021.12.005","volume":"341","author":"SV Morse","year":"2022","unstructured":"Morse SV, Mishra A, Chan TG, de Rosales TM, Choi R. Liposome delivery to the brain with rapid short-pulses of focused ultrasound and microbubbles. J Controlled Release. 2022;341:605\u201315.","journal-title":"J Controlled Release"},{"key":"3104_CR17","doi-asserted-by":"publisher","first-page":"103674","DOI":"10.1016\/j.jddst.2022.103674","volume":"75","author":"A Najmi","year":"2022","unstructured":"Najmi A, Wang S, Huang Y, Seefeldt T, Alqahtani Y, Guan X. 2-(2-Cholesteroxyethoxyl)ethyl-3\u2032-S-glutathionylpropionate (COXP) for brain-targeting liposomes. J Drug Deliv Sci Technol. 2022;75:103674.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3104_CR18","doi-asserted-by":"publisher","first-page":"6070","DOI":"10.1039\/D3AN01507F","volume":"148","author":"S Picciolini","year":"2023","unstructured":"Picciolini S, Rod\u00e0 F, Gualerzi A, Mangolini V, Forleo L, Mangolini A, Sesana S, Antoniou A, Re F, Seneci P, Bedoni M. SPRi analysis of molecular interactions of mApoE-functionalized liposomes as drug delivery systems for brain diseases. Analyst. 2023;148:6070\u20137.","journal-title":"Analyst"},{"key":"3104_CR19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1208\/s12248-021-00648-z","volume":"23","author":"F Juhairiyah","year":"2021","unstructured":"Juhairiyah F, de Lange ECM. Understanding drug delivery to the Brain using liposome-based strategies: studies that provide mechanistic insights are essential. AAPS J. 2021;23:114.","journal-title":"AAPS J"},{"key":"3104_CR20","doi-asserted-by":"publisher","first-page":"112999","DOI":"10.1016\/j.colsurfb.2022.112999","volume":"221","author":"MI Teixeira","year":"2023","unstructured":"Teixeira MI, Lopes CM, Amaral MH, Costa PC. Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): a current overview of active targeting in brain diseases. Colloids Surf B. 2023;221:112999.","journal-title":"Colloids Surf B"},{"key":"3104_CR21","doi-asserted-by":"crossref","unstructured":"Hersh AM, Alomari S, Tyler BM. Crossing the blood-brain barrier: advances in Nanoparticle Technology for Drug Delivery in Neuro-Oncology. Int J Mol Sci. 2022;23.","DOI":"10.3390\/ijms23084153"},{"key":"3104_CR22","doi-asserted-by":"crossref","unstructured":"Haqqani AS, B\u00e9langer K, Stanimirovic DB. Receptor-mediated transcytosis for brain delivery of therapeutics: receptor classes and criteria. Front Drug Delivery. 2024;4.","DOI":"10.3389\/fddev.2024.1360302"},{"key":"3104_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11373-006-9121-7","volume":"14","author":"R-q Huang","year":"2007","unstructured":"Huang R-q, Ke W-l, Qu Y-h, Zhu J-h, Pei Y-y, Jiang C. Characterization of lactoferrin receptor in brain endothelial capillary cells and mouse brain. J Biomed Sci. 2007;14:121\u20138.","journal-title":"J Biomed Sci"},{"key":"3104_CR24","doi-asserted-by":"publisher","first-page":"7011","DOI":"10.1074\/jbc.274.11.7011","volume":"274","author":"C Fillebeen","year":"1999","unstructured":"Fillebeen C, Descamps L, Dehouck M-P, Fenart L, Bena\u0131\u0308ssa M, Spik G, Cecchelli R, Pierce A. Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. J Biol Chem. 1999;274:7011\u20137.","journal-title":"J Biol Chem"},{"key":"3104_CR25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ejps.2017.06.002","volume":"106","author":"S Liu","year":"2017","unstructured":"Liu S, Zhang S-m, Ju R-j, Xiao Y, Wang X, Song X-l, Gu L-y, Cheng L, Li X-t. Chen G-r. antitumor efficacy of lf modified daunorubicin plus honokiol liposomes in treatment of brain glioma. Eur J Pharm Sci. 2017;106:185\u201397.","journal-title":"Eur J Pharm Sci"},{"key":"3104_CR26","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1124\/jpet.119.264127","volume":"374","author":"B Dos Santos Rodrigues","year":"2020","unstructured":"Dos Santos Rodrigues B, Lakkadwala S, Kanekiyo T, Singh J. Dual-modified liposome for targeted and enhanced gene delivery into mice Brain. J Pharmacol Exp Ther. 2020;374:354\u201365.","journal-title":"J Pharmacol Exp Ther"},{"key":"3104_CR27","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.lfs.2005.05.085","volume":"78","author":"B Ji","year":"2006","unstructured":"Ji B, Maeda J, Higuchi M, Inoue K, Akita H, Harashima H, Suhara T. Pharmacokinetics and brain uptake of lactoferrin in rats. Life Sci. 2006;78:851\u20135.","journal-title":"Life Sci"},{"key":"3104_CR28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/aps.2009.199","volume":"31","author":"HL Gao","year":"2010","unstructured":"Gao HL, Pang ZQ, Fan L, Hu KL, Wu BX, Jiang XG. Effect of lactoferrin- and transferrin-conjugated polymersomes in brain targeting: in vitro and in vivo evaluations. Acta Pharmacol Sin. 2010;31:237\u201343.","journal-title":"Acta Pharmacol Sin"},{"key":"3104_CR29","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.neuropharm.2017.08.015","volume":"125","author":"N Katila","year":"2017","unstructured":"Katila N, Bhurtel S, Shadfar S, Srivastav S, Neupane S, Ojha U, Jeong G-S, Choi D-Y. Metformin lowers \u03b1-synuclein phosphorylation and upregulates neurotrophic factor in the MPTP mouse model of Parkinson\u2019s disease. Neuropharmacology. 2017;125:396\u2013407.","journal-title":"Neuropharmacology"},{"key":"3104_CR30","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.nbd.2009.01.016","volume":"34","author":"JR Cannon","year":"2009","unstructured":"Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, Greenamyre JT. A highly reproducible rotenone model of Parkinson\u2019s disease. Neurobiol Dis. 2009;34:279\u201390.","journal-title":"Neurobiol Dis"},{"key":"3104_CR31","doi-asserted-by":"crossref","unstructured":"Jiang P-E, Lang Q-H, Yu Q-Y, Tang X-Y, Liu Q-Q, Li X-Y, Feng X-Z. Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson\u2019s Disease Model. J Visualized Experiments. 2019;143:e58653.","DOI":"10.3791\/58653"},{"key":"3104_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2022.04.003","volume":"346","author":"N Katila","year":"2022","unstructured":"Katila N, Duwa R, Bhurtel S, Khanal S, Maharjan S, Jeong J-H, Lee S, Choi D-Y, Yook S. Enhancement of blood\u2013brain barrier penetration and the neuroprotective effect of resveratrol. J Controlled Release. 2022;346:1\u201319.","journal-title":"J Controlled Release"},{"key":"3104_CR33","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.jconrel.2024.01.019","volume":"366","author":"ZQ Gu","year":"2024","unstructured":"Gu ZQ, Zhao H, Song YL, Kou YD, Yang WT, Li Y, Li X, Ding L, Sun ZH, Lin J, et al. PEGylated-liposomal astaxanthin ameliorates A\u03b2 neurotoxicity and Alzheimer-related phenotypes by scavenging formaldehyde. J Controlled Release. 2024;366:783\u201397.","journal-title":"J Controlled Release"},{"key":"3104_CR34","doi-asserted-by":"publisher","first-page":"4193","DOI":"10.2147\/IJN.S417928","volume":"18","author":"MK Shehata","year":"2023","unstructured":"Shehata MK, Ismail AA, Kamel MA. Combined Donepezil with Astaxanthin via Nanostructured lipid carriers effective delivery to Brain for Alzheimer\u2019s Disease in Rat Model. Int J Nanomed. 2023;18:4193\u2013227.","journal-title":"Int J Nanomed"},{"key":"3104_CR35","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1002\/jsfa.11435","volume":"102","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Gu Z, Liao Y, Li S, Xue Y, Firempong MA, Xu Y, Yu J, Smyth HDC, Xu X. Improved intestinal absorption and oral bioavailability of astaxanthin using poly (ethylene glycol)-graft-chitosan nanoparticles: preparation, in vitro evaluation, and pharmacokinetics in rats. J Sci Food Agric. 2022;102:1002\u201311.","journal-title":"J Sci Food Agric"},{"key":"3104_CR36","doi-asserted-by":"crossref","unstructured":"van Heijst N, Whiting P, Dutcher JR. Solubilization of hydrophobic astaxanthin in water by physical association with phytoglycogen nanoparticles. Biomacromolecules. 2024;25:4110\u20134117.","DOI":"10.1021\/acs.biomac.4c00214"},{"key":"3104_CR37","doi-asserted-by":"crossref","unstructured":"Gherabli A, Grimi N, Lemaire J, Vorobiev E, Lebovka N. Extraction of Valuable Biomolecules from the Microalga Haematococcus pluvialis assisted by Electrotechnologies. Molecules. 2023;28.","DOI":"10.3390\/molecules28052089"},{"key":"3104_CR38","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s11671-017-2119-4","volume":"12","author":"A Hardiansyah","year":"2017","unstructured":"Hardiansyah A, Yang M-C, Liu T-Y, Kuo C-Y, Huang L-Y, Chan T-Y. Hydrophobic drug-loaded PEGylated magnetic liposomes for drug-controlled release. Nanoscale Res Lett. 2017;12:355.","journal-title":"Nanoscale Res Lett"},{"key":"3104_CR39","doi-asserted-by":"publisher","first-page":"854","DOI":"10.3109\/03639045.2012.684390","volume":"39","author":"J Lalani","year":"2013","unstructured":"Lalani J, Rathi M, Lalan M, Misra A. Protein functionalized tramadol-loaded PLGA nanoparticles: preparation, optimization, stability and pharmacodynamic studies. Drug Dev Ind Pharm. 2013;39:854\u201364.","journal-title":"Drug Dev Ind Pharm"},{"key":"3104_CR40","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1002\/adhm.201300598","volume":"3","author":"JH Fang","year":"2014","unstructured":"Fang JH, Lai YH, Chiu TL, Chen YY, Hu SH, Chen SY. Magnetic core-shell nanocapsules with dual-targeting capabilities and co-delivery of multiple drugs to treat brain gliomas. Adv Healthc Mater. 2014;3:1250\u201360.","journal-title":"Adv Healthc Mater"},{"key":"3104_CR41","doi-asserted-by":"crossref","unstructured":"Faucheux BA, Nillesse N, Damier P, Spik G, Mouatt-Prigent A, Pierce A, Leveugle B, Kubis N, Hauw JJ, Agid Y. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc Natl Acad Sci. 1995;92:9603\u20137.","DOI":"10.1073\/pnas.92.21.9603"},{"key":"3104_CR42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/2045-8118-10-33","volume":"10","author":"DE Eigenmann","year":"2013","unstructured":"Eigenmann DE, Xue G, Kim KS, Moses AV, Hamburger M, Oufir M. Comparative study of four immortalized human brain capillary endothelial cell lines, hCMEC\/D3, hBMEC, TY10, and BB19, and optimization of culture conditions, for an in vitro blood\u2013brain barrier model for drug permeability studies. Fluids Barriers CNS. 2013;10:33.","journal-title":"Fluids Barriers CNS"},{"key":"3104_CR43","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13024-023-00676-7","volume":"18","author":"MT Henrich","year":"2023","unstructured":"Henrich MT, Oertel WH, Surmeier DJ, Geibl FF. Mitochondrial dysfunction in Parkinson\u2019s disease \u2013 a key disease hallmark with therapeutic potential. Mol Neurodegeneration. 2023;18:83.","journal-title":"Mol Neurodegeneration"},{"key":"3104_CR44","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41593-021-00989-0","volume":"25","author":"R Wright","year":"2022","unstructured":"Wright R. Mitochondrial dysfunction and Parkinson\u2019s disease. Nat Neurosci. 2022;25:2\u20132.","journal-title":"Nat Neurosci"},{"key":"3104_CR45","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","volume":"22","author":"MG Tansey","year":"2022","unstructured":"Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022;22:657\u201373.","journal-title":"Nat Rev Immunol"},{"key":"3104_CR46","doi-asserted-by":"crossref","unstructured":"Ara\u00fajo B, Caridade-Silva R, Soares-Guedes C, Martins-Macedo J, Gomes ED, Monteiro S, Teixeira FG. Neuroinflammation and parkinson\u2019s disease-from neurodegeneration to therapeutic opportunities. Cells. 2022;11:2908.","DOI":"10.3390\/cells11182908"},{"key":"3104_CR47","doi-asserted-by":"crossref","unstructured":"Pizarro-Galleguillos BM, Kunert L, Br\u00fcggemann N, Prasuhn J. Neuroinflammation and mitochondrial dysfunction in Parkinson\u2019s disease: connecting neuroimaging with pathophysiology. Antioxid (Basel). 2023;12:1411.","DOI":"10.3390\/antiox12071411"},{"key":"3104_CR48","doi-asserted-by":"crossref","unstructured":"Peggion C, Cal\u00ec T, Brini M. Mitochondria Dysfunction and Neuroinflammation in Neurodegeneration: Who Comes First? Antioxidants (Basel). 2024;13.","DOI":"10.3390\/antiox13020240"},{"key":"3104_CR49","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3390\/md17020123","volume":"17","author":"JH Han","year":"2019","unstructured":"Han JH, Lee YS, Im JH, Ham YW, Lee HP, Han SB, Hong JT. Astaxanthin ameliorates lipopolysaccharide-induced neuroinflammation, oxidative stress and memory dysfunction through inactivation of the signal transducer and activator of transcription 3 pathway. Mar Drugs. 2019;17:123.","journal-title":"Mar Drugs"},{"key":"3104_CR50","doi-asserted-by":"publisher","first-page":"8793","DOI":"10.1021\/jf9019745","volume":"57","author":"YJ Kim","year":"2009","unstructured":"Kim YJ, Kim YA, Yokozawa T. Protection against oxidative stress, inflammation, and apoptosis of high-glucose-exposed proximal tubular epithelial cells by astaxanthin. J Agric Food Chem. 2009;57:8793\u20137.","journal-title":"J Agric Food Chem"},{"key":"3104_CR51","doi-asserted-by":"publisher","first-page":"7639109","DOI":"10.1155\/2020\/7639109","volume":"2020","author":"G Cui","year":"2020","unstructured":"Cui G, Li L, Xu W, Wang M, Jiao D, Yao B, Xu K, Chen Y, Yang S, Long M, et al. Astaxanthin protects ochratoxin A-induced oxidative stress and apoptosis in the heart via the Nrf2 pathway. Oxidative Med Cell Longev. 2020;2020:7639109.","journal-title":"Oxidative Med Cell Longev"},{"key":"3104_CR52","doi-asserted-by":"publisher","first-page":"6125","DOI":"10.3390\/md12126125","volume":"12","author":"Q Wu","year":"2014","unstructured":"Wu Q, Zhang XS, Wang HD, Zhang X, Yu Q, Li W, Zhou ML, Wang XL. Astaxanthin activates nuclear factor erythroid-related factor 2 and the antioxidant responsive element (Nrf2-ARE) pathway in the brain after subarachnoid hemorrhage in rats and attenuates early brain injury. Mar Drugs. 2014;12:6125\u201341.","journal-title":"Mar Drugs"},{"key":"3104_CR53","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3390\/md11041019","volume":"11","author":"Q Ye","year":"2013","unstructured":"Ye Q, Zhang X, Huang B, Zhu Y, Chen X. Astaxanthin suppresses MPP+-Induced oxidative damage in PC12 cells through a Sp1\/NR1 signaling pathway. Mar Drugs. 2013;11:1019\u201334.","journal-title":"Mar Drugs"},{"key":"3104_CR54","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1111\/j.1471-4159.2008.05743.x","volume":"107","author":"Y Ikeda","year":"2008","unstructured":"Ikeda Y, Tsuji S, Satoh A, Ishikura M, Shirasawa T, Shimizu T. Protective effects of astaxanthin on 6-hydroxydopamine-induced apoptosis in human neuroblastoma SH-SY5Y cells. J Neurochem. 2008;107:1730\u201340.","journal-title":"J Neurochem"},{"key":"3104_CR55","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.fct.2010.10.029","volume":"49","author":"DH Lee","year":"2011","unstructured":"Lee DH, Kim CS, Lee YJ. Astaxanthin protects against MPTP\/MPP+-induced mitochondrial dysfunction and ROS production in vivo and in vitro. Food Chem Toxicol. 2011;49:271\u201380.","journal-title":"Food Chem Toxicol"},{"key":"3104_CR56","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41531-022-00370-3","volume":"8","author":"MG Stykel","year":"2022","unstructured":"Stykel MG, Ryan SD. Nitrosative stress in Parkinson\u2019s disease. Npj Parkinson\u2019s Disease. 2022;8:104.","journal-title":"Npj Parkinson\u2019s Disease"},{"key":"3104_CR57","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1139\/o11-058","volume":"90","author":"P Rawat","year":"2012","unstructured":"Rawat P, Kumar S, Sheokand N, Raje CI, Raje M. The multifunctional glycolytic protein glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a novel macrophage lactoferrin receptor1This article is part of special issue entitled Lactoferrin and has undergone the Journal\u2019s usual peer review process. Biochem Cell Biol. 2012;90:329\u201338.","journal-title":"Biochem Cell Biol"},{"key":"3104_CR58","doi-asserted-by":"publisher","first-page":"8038","DOI":"10.1039\/D0FO01176B","volume":"11","author":"C-C Wang","year":"2020","unstructured":"Wang C-C, Shi H-H, Xu J, Yanagita T, Xue C-H, Zhang T-T, Wang Y-M. Docosahexaenoic acid-acylated astaxanthin ester exhibits superior performance over non-esterified astaxanthin in preventing behavioral deficits coupled with apoptosis in MPTP-induced mice with Parkinson\u2019s disease. Food Funct. 2020;11:8038\u201350.","journal-title":"Food Funct"},{"key":"3104_CR59","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.neures.2020.04.003","volume":"165","author":"D-F Shen","year":"2021","unstructured":"Shen D-F, Qi H-P, Ma C, Chang M-X, Zhang W-N, Song R-R. Astaxanthin suppresses endoplasmic reticulum stress and protects against neuron damage in Parkinson\u2019s disease by regulating miR-7\/SNCA axis. Neurosci Res. 2021;165:51\u201360.","journal-title":"Neurosci Res"},{"key":"3104_CR60","doi-asserted-by":"crossref","unstructured":"Esteves M, Crist\u00f3v\u00e3o AC, Saraiva T, Rocha SM, Baltazar G, Ferreira L, Bernardino L. Retinoic acid-loaded polymeric nanoparticles induce neuroprotection in a mouse model for Parkinson\u2019s disease. Front Aging Neurosci. 2015;7.","DOI":"10.3389\/fnagi.2015.00020"},{"key":"3104_CR61","doi-asserted-by":"crossref","unstructured":"Sawada M, Imamura K, Nagatsu T. Role of cytokines in inflammatory process in Parkinson\u2019s disease. J Neural Transmission-Supplement. 2006;70:373\u201381.","DOI":"10.1007\/978-3-211-45295-0_57"},{"key":"3104_CR62","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1523\/JNEUROSCI.19-09-03440.1999","volume":"19","author":"S Hunot","year":"1999","unstructured":"Hunot S, Dugas N, Faucheux B, Hartmann A, Tardieu M, Debr\u00e9 P, Agid Y, Dugas B, Hirsch EC. FcepsilonRII\/CD23 is expressed in Parkinson\u2019s disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci. 1999;19:3440\u20137.","journal-title":"J Neurosci"},{"key":"3104_CR63","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3233\/JPD-239901","volume":"13","author":"K McFarthing","year":"2023","unstructured":"McFarthing K, Buff S, Rafaloff G, Fiske B, Mursaleen L, Fuest R, Wyse RK, Stott SRW. Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2023 update. J Parkinson\u2019s Disease. 2023;13:427\u201339.","journal-title":"J Parkinson\u2019s Disease"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03104-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-025-03104-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03104-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T06:15:23Z","timestamp":1738649723000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-025-03104-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3104"],"URL":"https:\/\/doi.org\/10.1186\/s12951-025-03104-8","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"30 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In vivo studies were conducted using protocols reviewed and approved by the Institutional Animal Care and Use Committee of Keimyung University (KM2023-017).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors are consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}